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Background: Data from the Wisconsin newborn screening (NBS) study show that neonatally diagnosed infants are at risk of early Pseudomonas
aeruginosa (PsA) acquisition. We have had NBS since 1981 and in 2003, introduced PsA-free ‘segregation’ from older patients for children ≤5.
This study investigated the effect of simple ‘segregation' on acquisition of respiratory pathogens.
Methods: Sputum culture results (n=2814) and details of antibiotic use before (1999–2002) and after (2004–2007) ‘segregation’ were collected.
Results: Each year each child provided an average of 4.6 samples for culture. There was a significant decrease (p≤0.001 Chi2) in the acquisition
of mucoid (from 5.9% of children to 1.0%) but not non-mucoid PsA (22.3% and 22.7%, respectively) after ‘segregation’. There was no significant
change in other respiratory pathogens.
Conclusions: Young children with CF diagnosed via NBS can be protected from the acquisition of mucoid PsA by ‘segregation’ and the
acquisition of non-mucoid PsA is likely to be from environmental sources outside the hospital.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Progression of lung disease in cystic fibrosis (CF) is the
major determinant of quality of life and of survival. Infection of
airway secretions with organisms including Staphylococcus
aureus (SA) and Pseudomonas aeruginosa (PsA) result in
chronic inflammation of the airways and ultimately respiratory
failure. PsA is recognised as the most common pathogenic
bacteria in CF and there is evidence that duration of survival is
related to age of PsA acquisition [1] although the acquisition of
PsA per se does not preclude longevity [2]. The rate of
worsening of lung disease in children with CF has been shown
to accelerate after the acquisition of PsA [3,4].
Screening programs for the neonatal diagnosis of CF are
being introduced worldwide. Such screening programs mean⁎ Corresponding author. Department of Respiratory Medicine, The Children's
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doi:10.1016/j.jcf.2009.07.007that the median age at diagnosis of children with CF will
significantly decrease and that centres will look after young
infants without respiratory infection at diagnosis. Data from
the hallmark study of newborn screening carried out in
Wisconsin have shown that such infants are at risk of early
PsA acquisition supposedly from older patients with CF.
Indeed, although there was no significant difference in the
overall rate of PsA acquisition to 9 years in the screened and
non-screened groups, the PsA-free survival time was signif-
icantly different in the screened and non-screened groups
depending on the study site. In the site where the clinic
environment was older and smaller, and where adult and
paediatric patients were seen simultaneously, the mean age
of first PsA acquisition was 52 weeks of age. This as compared
to first acquisition at 289 weeks in a newer centre where
clinics dedicated to children were held [5]. These investigators
later showed that this disparity disappeared after the
introduction of a dedicated paediatric facility to replace the
older site [6].
While no evidence of cross-infectivity with PsA was found
in a surveillance study performed in Staffordshire [7], in recentd by Elsevier B.V. All rights reserved.
Table 1
Age distribution of children from whom culture results were obtained.
Age (years)
b1 1 2 3 4 5 Total≤5
1999 12 15 12 16 16 19 90
2000 10 15 12 12 16 17 82
2001 8 9 14 14 15 12 72
2002 14 13 11 14 14 11 77
All ‘pre’ 44 52 49 56 61 59 321
2004 10 12 17 12 10 13 74
2005 12 12 14 15 12 10 75
2006 10 15 13 11 14 12 75
2007 10 11 15 12 12 15 75
All ‘post’ 42 50 59 50 48 50 299
‘pre’ indicates years of the study before introduction of the ‘segregation’ policy
while ‘post’ refers to the years since the introduction of the policy.
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by CF centres throughout the world. As a result of these reports,
separation polices based on PsA status have been instituted in
many CF centres. These have included separation of patients
during hospitalisations and varying degrees of separation of
patients during clinic attendance—generally referred to as
‘segregation’. The sophistication of ‘segregation’ systems
employed by particular institutions is often dependent upon
local factors such as hospital physical space, staffing, treatment
regimens, financial resources, as well as infection control
policies.
Newborn screening for CF has been available in NSW since
1981 and we have had extensive experience in dealing with
asymptomatic infants following early diagnosis. To potentially
reduce transmission of respiratory infections from older
patients, in May 2003 we instituted a simple and cost-effective
means of ‘segregation’ of young children with CF from older
children, adolescents and young adults attending our clinic.
Here, we report the effect of this practice on the respiratory
organisms isolated from respiratory secretions in children with
CF aged 5 years and younger, diagnosed via newborn
screening.
2. Methods
This study was a retrospective audit of all sputum culture
results in children aged 5 years and under for 4 years prior to,
and after, the institution of our ‘segregation’ policy. The policy
was instituted in April 2003 and was completed by the end of
May 2003. Thus, culture results for the years 1999–2002 were
considered ‘pre-segregation’ and for 2004–2007 as ‘post-
segregation’. All cultures performed from 1st January to 31st
December each year were included in that year's results.
Prior to the institution of the ‘segregation’ policy, one large,
all age clinic was held one morning per week and any child (0–
18 years) could attend the clinic provided an appointment was
available and there was open and free mixing of patients in the
clinic waiting area. The ‘segregation’ policy was as follows:
outpatient clinics, were designated by colour as ‘red’ (pre-
school age), ‘blue’ (primary school age) or ‘green’ (secondary
school age). Attendance at ‘red’ clinics was restricted to those
children 5 and under who were PsA-free. Children under 5 who
were already colonised with PsA at the time ‘segregation’ was
introduced were placed in the ‘blue’ clinic. Children who
acquired PsA whilst attending the red clinic were treated
aggressively with anti-PsA antibiotics (either inhaled or
intravenous) and were removed from the ‘red’ clinic until
their sputum cultures were free of PsA. The booking system
was altered to reflect these ‘coloured’ clinics and the
appointments clerks instructed to adhere to the colour codes.
If an older child with PsA attended the red clinic, they were
placed in an isolation room. Attendance records for each clinic
were retained to monitor compliance with this system.
Additional infection control measures such as the removal of
toys from the waiting room and hand cleansing were also
introduced. A CF Day Treatment Centre was also opened in a
separate building where advice and treatment for acutely illchildren were provided. All inpatients were treated in single
rooms or in rooms shared with children without CF.
Few of the children were able to successfully expectorate and
so sputum samples were collected by experienced nurses using
a deep pharyngeal suction technique. This involved introduc-
tion of a 10F soft plastic catheter attached to suction over the
tongue and into the pharynx. The child was instructed to huff
and then cough, or if too young to follow instruction, the
catheter was gently moved about to stimulate a cough, and any
sputum resulting was suctioned into the specimen tube.
Sputum samples were cultured using standard microbiolog-
ical techniques. Specifically, inoculated blood agar and
MacConkey agar plates were incubated at 35 °C for 48 h in
CO2 and air incubators respectively. Identification of PsA was
usually confirmed as an oxidase positive Gram-negative rod
which grew at 42 °C, did not grow anaerobically and produced
green pigmentation when cultured on ‘Sensitest’ agar. Other
nonfermentative Gram-negative bacilli, and atypical PsA
strains, were identified using the API-20NE reagent strip or
Vitek 2 GN identification cardsystems. From late 2004, a
mannitol salt agar plate was also used for easier identification of
SA and a chocolate agar plate with bacitracin incubated
anaerobically for 48 h was introduced to optimise the recovery
of HI (all reagents were from Biomerieux, Australia or France).
The organisms studied were Escherichia coli and other
coliforms (E. coli), HI, SA, methicillin resistant S. aureus
(MRSA), non-mucoid P. aeruginosa (nmPsA) and mucoid P.
aeruginosa (mPsA). A child was considered to have isolated an
organism under investigation if at least one of the cultures
performed for the year was positive for the organism.
Group and statistical analysis was performed using SPSS for
Windows (version 15, SPSS Inc 2006). Comparison of rates of
infection and antibiotic use before and after the introduction of
‘segregation’ was done using Chi-square analysis and differ-
ences were considered significantly different if pb0.05.
3. Results
Between 72 and 90 children aged 5 years and under were
seen in each year of the study. The age distribution of children
seen for each year is presented in Table 1. An average of 80.3
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‘segregation’ and after ‘segregation’ an average of 74.8 children
were cared for by the CF clinic each year. There were equal
numbers of male and female children in each group. In
accordance with the Cystic Fibrosis Standards of Care Guide-
lines published by the Australian CF Foundation, which state
that each child should have at least 4 CF-specific reviews every
year, these children had a mean±se of 4.53±0.08 (median=4)
sputum cultures analysed prior to ‘segregation’ and 4.63±0.07
(median=4) after ‘segregation’. The results of 2837 sputum
cultures were analysed for the study in total.
Adherence to the ‘coloured’ clinic booking scheme was high
and was maintained over time after the institution of
‘segregation’. In 2004, 96.8% of the children attending ‘red’
clinics were 5 and under, for 2005, 2006 and 2007 the
corresponding figures were 97.5%, 94.4%, and 95.9%,
respectively.
After the introduction of ‘segregation’, the rate of infection
with mPsA was significantly reduced in all age groups (Table 2
and Fig. 1). The reduction in isolation of mPsA was particularly
evident for those who were 4 and 5 years of age, where the rates
of infection decreased from more than 10% of children to 2% or
less. There was however, no reduction in the proportion of
children isolating nmPsA, where 22.3% of all children under 5
isolated the organism before, and 22.7% after, institution of the
policy. Similarly, the proportion of children isolating E. coli,
SA and MRSA was unchanged. A significant increase in the
isolation of HI occurred from 2005 as a result of a change in
microbiology laboratory procedures as outlined above.
There was no significant change in the use of intravenous
anti-PsA antibiotics for those with nmPsA after introduction of
the policy (Table 3), slightly more than 50% of children before
‘segregation’ and slightly less than 50% afterwards (p=0.33).
The number of intravenous antibiotic courses administered per
child was also roughly equivalent before (1.36 courses/child)Table 2
Age distribution of culture results before and after the institution of the
‘segregation’ policy.
Age (years)
b1 1 2 3 4 5 All≤5
E. coli ‘Pre’ 57.3 57.9 46.8 35.0 23.1 29.2 40.7
‘Post’ 56.3 74.4 42.5 29.4 23.5 11.5 39.8
HI ‘Pre’ 3.9 0 6.1 5.4 6.5 8.5 5.2
‘Post’ 11.3 20.8 5.0 14.5 15.5 17.5 14.3⁎⁎
SA ‘Pre’ 38.7 29.6 47.6 60.3 49.6 47.4 45.5
‘Post’ 50.4 32.9 45.7 48.8 68.7 56.6 50.5
MRSA ‘Pre’ 0 0 2.1 2.1 1.7 2.3 1.3
‘Post’ 0 0 1.8 2.3 0 2.1 1.0
nmPsA ‘Pre’ 2.1 22.2 23.0 30.4 26.1 25.7 22.3
‘Post’ 9.2 25.0 24.8 18.3 28.5 27.5 22.7
mPsA ‘Pre’ 0 1.7 0 5.4 12.9 10.7 5.9
‘Post’ 0 0 1.9 2.1 0 2.1 1.0⁎
‘Pre’ indicates years of the study before introduction of the ‘segregation’ policy
while ‘Post’ refers to the years since the introduction of the policy. Values are
the percentage of children of that age isolating the organism in question at least
once during the relevant period. A significant difference in the prevalence of
organisms for all children aged 5 and under ‘Pre’ and ‘Post’ are shown
⁎p≤0.001, ⁎⁎p≤0.0001.and after (1.17) ‘segregation’ and similarly, the number of
children who were prescribed inhaled antibiotics did not change
significantly (p=0.15).
4. Discussion
The results of this study suggest that young children
diagnosed via newborn screening can be protected from the
acquisition of mPsA by the institution of a simple ‘segregation’
policy. Moreover, importantly, the results also suggest that the
acquisition of other respiratory organisms, such as nmPsA is
most likely from sources outside the hospital environment.
As mentioned above, a change to microbiological culture
techniques in late 2004, had increased the likelihood of
detecting both HI and SA. This resulted in a very significant
increase in the detection of HI, but this was not the case for SA
isolation where only a slight increase was seen from 2005
onward. Our rates of infection with both PsA and SA are very
similar to those reported for this age group in the US CF
Registry, whereas our rate of HI infection is somewhat lower,
and that for MRSA is substantially lower [8]. While we used
deep suction via the oropharynx to obtain sputum samples
rather than oropharyngeal swabs for microbiological culture in
this study, such specimens do not always predict the presence of
bacterial pathogens, particularly PsA, in the lower airways of
young children with CF [9] and so these rates of infection
should be interpreted with caution.
While a decrease in the acquisition of PsA has been
demonstrated after the opening of a dedicated paediatric clinic
to replace an older style unit treating both adults and children
[6], ours is not the first study to report the continued acquisition
of PsA after the introduction of segregation policies. Mainte-
nance of the same rate of acquisition of PsA after the
introduction of strict segregation has also been reported in
previously PsA-free patients in an adult clinic in Manchester
[10], while a longitudinal study of infants and young children
with CF, demonstrated newly acquired PsA isolates have
unique genotypes [11]. Genetic typing of PsA isolates from a
paediatric centre in Vancouver [12] has also allowed investi-
gators to conclude that the major source of acquisition of PsA in
CF appears to be from the environment, although the precise
origin is unclear as demonstrated by recent work from Belgium
attempting to identify an environmental source for those with
newly acquired PsA [13]. The results of our study lend support
to this proposition. Children with positive PsA cultures were
excluded from the ‘red’ clinic after the introduction of the
segregation policy, yet there was no diminution in the
prevalence of nmPsA after this change. This was despite good
adherence to the policy in that at least 95% of children attending
this designated PsA-free clinic met the attendance restrictions.
The main factor limiting our conclusions was the absence of
genomic fingerprinting of the PsA strains before and after
institution of our ‘segregation’ policy. Given that this study was
in the form of a retrospective review, clearly this was impossible
to pursue. Children are typically infected with mPsA at an older
age than when they acquire nmPsA [14], it is likely that the
decrease in mPsA that we found was indeed due to reduced
Fig. 1. Culture results for all children aged 5 years and younger before (1999–2002) and after (2004–2007) the institution of the ‘segregation’ policy.
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observed decrease in mPsA was not related to a more aggressive
treatment regimen for those acquiring nmPsA after the
introduction of the policy, as the use of antibiotics did not
change significantly after ‘segregation’.
Kosorok and colleagues have delineated a number of risk
factors for acquisition of PsA early in life and found that
children using aerosol therapies were significantly more likely
to acquire PsA [6]. Few children 5 years and under use aerosol
therapies in our clinic; rhDNAse is not available for this age
group in Australia, only one child in the study cohort was using
nebulised hypertonic saline and there was no change in the
frequency of bronchodilator or inhaled corticosteroid use after
institution of our ‘segregation policy’. There was no change in
the frequency of inhaled antibiotic use during the study.
Prophylaxis with flucloxacillin has been used in our clinic for
more than 20 years and remains a routine therapy for the first
12 months of life. Similarly, there were no changes in
respiratory consultants within the clinic during the period of
the study and the nurses who obtained the sputum samples were
unchanged. These observations, coupled with the absence of
change in the prevalence of nmPsA support our conclusion that
the observed decrease in mPsA was unrelated to changes in
aerosol therapies, practice patterns or changes in personnel.Table 3
Use of anti-pseudomonal antibiotics for nmPsA isolation before and after
institution of the ‘segregation’ policy.
Pre Post
Number of children with nmPsA 61 66
Receiving iv antibiotics (%) 33 (54.1%) 30 (45.5%)
Courses of iv antibiotics 45 35
Receiving inhaled antibiotics (%) 55 (90.2%) 55 (83.3%)
As needed inhaled antibiotics (%) 50 (90.9%) 52 (94.6%)
‘Pre’ indicates total values for all years of the study before introduction of the
‘segregation’ policy while ‘Post’ refers to the total for years since the introduction
of the policy.
Only children isolating nmPsA in the absence of mPsA are included.Methods employed by CF clinics to limit patient-to-patient
transmission of PsA from are many and varied. Some clinics are
able to perform genetic fingerprinting on PsA isolates and thus
organise their clinics according to the strain of PsA present in
each patient. Our CF clinic faced constraints in the availability
of physical space and personnel and so we took the least
expensive option, to simply separate those who were free from
PsA from all others in an attempt to delay the acquisition of
PsA. Although we did not delay the acquisition of PsA per se,
we did diminish the acquisition of a more treatment resistant
form of PsA [4]. This mucoid form of PsA is associated with a
worse prognosis for patients with CF than the non-mucoid form
which has been considered by some investigators to be of no
greater significance than other respiratory pathogens [15] or
even harmless [4].
We have shown that a reduction in the rate of infection with
mPsA in young children with CF diagnosed via newborn
screening is possible using a simple segregation policy.
Furthermore, we have shown that it is likely that infants and
young children with CF acquire nmPsA from an environmental
source rather from other patients with CF. We therefore suggest
that centres who have established or who are considering
adopting programs for newborn screening may be able to delay
the acquisition of mPsA but not nmPsA by undertaking a simple
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